Piramal Pharma Limited, through promoter Ajay G. Piramal, has submitted a declaration to the stock exchanges confirming that the promoters and promoter group did not encumber any shares during the financial year 2025-2026.
The disclosure was made under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, also referred to as the SEBI Takeover Code or SEBI SAST. The declaration was submitted to BSE Limited and the National Stock Exchange of India Limited on April 6, 2026.
Piramal Pharma is listed on BSE with scrip code 543635 and on NSE under the symbol PPLPHARMA. The filing was made public by the exchanges on June 29, 2026, after being received and processed.
Regulation 31(4) of the SEBI Takeover Code requires promoters to disclose any encumbrance created on company shares during a financial year. Encumbrance includes pledges, liens, or any other charge on shares. The promoters confirmed that no encumbrance was created directly or indirectly on shares of Piramal Pharma during FY26.
The declaration was signed by Ajay G. Piramal on behalf of the promoter and promoter group. Promoter-held shares in Piramal Pharma remained free of encumbrance through the financial year ended March 31, 2026. The disclosure meets the annual compliance requirement for listed company promoters under the SEBI SAST regulations.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.